Zobrazeno 1 - 10
of 21
pro vyhledávání: '"V. L. King"'
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 30:33-42
Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs. The biologic effects of dirlotapide, weight loss, decreased food intake, increased fecal fat, decreased serum chol
Autor:
A. L. Schroeder, Benjamin M. Bohrer, Dustin Dee Boler, V. L. King, J. L. Spruill, D. P. Thompson, S. S. Johnson, J. M. Kyle, W. L. Flowers
Publikováno v:
Journal of animal science. 92(10)
Objectives were to evaluate the administration of an anti-gonadotropin releasing factor (GnRF) analog on suppression of estrus, consistency of feed intake, and growth performance in market gilts and to investigate the impact the physiological changes
Publikováno v:
Europe PubMed Central
A 110-kDa Borrelia burgdorferi fusion protein, Escherichia coli expressing the fusion protein, transformed E. coli lacking the fusion protein insert, and lyophilized whole B. burgdorferi bacteria were compared for immunogenicity in C3H/He mice. Immun
Publikováno v:
Journal of veterinary pharmacology and therapeutics. 30
An overview of the pharmacokinetics of dirlotapide in beagle dogs is presented. The following mean parameters were observed after a 0.3-mg/kg i.v. dose of dirlotapide: plasma clearance of 7.8 mL/min/kg and volume of distribution of 1.3 L/kg. Followin
Autor:
J. S. Eagleson, A. A. Ramudo, S. J. Sunderland, J. A. Wren, S. L. Campbell, V. L. King, J. Gossellin
Publikováno v:
Journal of veterinary pharmacology and therapeutics. 30
Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America. A total of 335 obese dogs of various breeds were randomized to dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered o
Autor:
V. L. King, J. A. Wren, M. J. Krautmann, M. A. Hickman, J. Gossellin, T. J. Schmahai, R. L. Kerlin
Publikováno v:
Journal of veterinary pharmacology and therapeutics. 30
The safety of dirlotapide in dogs was evaluated in two studies with parallel designs. In an acute tolerance study, 24 beagles (six dogs per treatment) were treated orally once daily for 14 days with placebo or dirlotapide at 2.5, 5.0, or 10.0 mg/kg/d
Publikováno v:
Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 15(3)
The present study examined the short-term stability of personality trait scores from the Revised NEO Personality Inventory (NEO-PI-R) among 230 opioid-dependent outpatients. The NEO-PI-R is a 240-item empirically developed measure of the five-factor
Publikováno v:
American journal of veterinary research. 60(4)
To evaluate the effect of saline (0.9% NaCl) solution administered IV to induce diuresis on 15 dimensional variables of the kidneys, size of renal pelvis, and diameter of the cranial part of the ureters.25 dogs without evidence of renal disease that
Publikováno v:
Journal of the American Veterinary Medical Association. 214(4)
To compare the clinical and clinicopathologic findings in and prognosis for cats with lymphocytic portal hepatitis (LPH) versus cats with acute or chronic cholangiohepatitis (CH).Retrospective study.25 cats with LPH; 16 cats with CH (7 acute, 9 chron
Publikováno v:
Journal of consulting and clinical psychology. 66(1)
This study examined the predictive validity of Structured Clinical Interview for DSM-III-R (Spitzer, Williams, Gibbon,First, 1990) based substance dependence diagnoses (i.e., cocaine, sedative, and alcohol) for 518 opioid-dependent outpatients enteri